Compugen Ltd at Stifel Virtual Targeted Oncology Forum Transcript
All right. Good morning, everyone. I'm Stephen Willey, one of the senior biotech analysts here at Stifel and glad to have with us as part of the next session with the CEO of Compugen, Eran Ophir. Eran, thanks for joining us today.
Any opening comments or introductory statements you want to give before we jump into Q&A?
Sure. So maybe consult a few words, high-level description of Compugen. So Compugen is a pioneer in AI-based computational discovery. We're doing actually AI before all of this recent hype of AI. And we use this AI-based platform to identify new drug targets in the field of immuno oncology.
And we have a validated computational platform. And why it's validated? Because we showed again and again, we can use computational tools to identify new drug targets. And we have internal assets that we'll describe together the discussion today that were discovered using a computational platform.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
